title: Pharmacokinetics of tamsulosin hydrochloride in patients with renal impairment: effects of alpha 1-acid glycoprotein.
abstract: The pharmacokinetics of tamsulosin hydrochloride in patients with renal impairment were compared with those in healthy volunteers, and the factors that influenced plasma levels of tamsulosin were elucidated. A single oral dose of 0.2 mg of tamsulosin was given and blood and urine samples were obtained for 36 hours after administration. Unbound plasma concentration of tamsulosin was measured by a combination of equilibrium dialysis and liquid chromatography tandem mass spectrometry methods to examine the effect of protein binding on the pharmacokinetics of tamsulosin. Mean values for maximum concentration (Cmax) and area under the concentration-time curve (AUC) of total drug (Cmax,t and AUC1) in patients with renal impairment were 73% and 211% greater, respectively, than those in healthy volunteers. Mean Cmax and AUC of unbound drug (Cmax,u and AUCu), however, were almost the same in the two groups. A high correlation was found between alpha 1-acid glycoprotein (alpha 1-AGP) concentration and AUCt, but no correlation was found between alpha 1-AGP concentration and AUCu,0-36) or between creatinine clearance (ClCR) and AUCu,0-36). These results show that in patients with renal impairment, the pharmacokinetics of tamsulosin are affected by the change in protein binding that is associated with alteration of plasma alpha 1-AGP concentration, but are not largely affected by the decrease in the renal excretion. Although total tamsulosin levels increased as plasma protein binding increased, unbound tamsulosin levels (which are directly associated with the pharmacologic effects) remained unchanged in these patients.
authors.affiliation: Department of Urology, University of Tsukuba, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Koiso
authors.forename: H
authors.initials: H
authors.lastname: Akaza
authors.forename: K
authors.initials: K
authors.lastname: Kikuchi
authors.forename: K
authors.initials: K
authors.lastname: Aoyagi
authors.forename: S
authors.initials: S
authors.lastname: Ohba
authors.forename: M
authors.initials: M
authors.lastname: Miyazaki
authors.forename: M
authors.initials: M
authors.lastname: Ito
authors.forename: T
authors.initials: T
authors.lastname: Sueyoshi
authors.forename: H
authors.initials: H
authors.lastname: Matsushima
authors.forename: H
authors.initials: H
authors.lastname: Kamimura
authors.forename: T
authors.initials: T
authors.lastname: Watanabe
authors.forename: S
authors.initials: S
authors.lastname: Higuchi
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000097:blood / Q000493:pharmacokinetics*; D000368:Aged; D001798:Blood Proteins / Q000378:metabolism; D004347:Drug Interactions; D006801:Humans; D007674:Kidney Diseases / Q000097:blood / Q000378:metabolism*; D008099:Liver / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D009961:Orosomucoid / Q000378:metabolism*; D011485:Protein Binding; D012016:Reference Values; D013449:Sulfonamides / Q000097:blood / Q000493:pharmacokinetics*; D000077409:Tamsulosin
chemical_list: D000317:Adrenergic alpha-Antagonists; D001798:Blood Proteins; D009961:Orosomucoid; D013449:Sulfonamides; D000077409:Tamsulosin